Welcome to our dedicated page for Venus Concept news (Ticker: VERO), a resource for investors and traders seeking the latest updates and insights on Venus Concept stock.
Venus Concept Inc. (NASDAQ: VERO) is a medical aesthetic technology company whose news flow reflects both its product developments and its capital and strategic actions. The company describes itself as a global medical aesthetic technology leader with a portfolio of minimally invasive and non-invasive systems for body, face, skin and hair restoration applications. Its updates often highlight device platforms such as Venus Versa, Venus Legacy, Venus Bliss, Venus Viva, Venus Epileve, AI.ME and, more recently, the next-generation Venus NOVA platform.
On this news page, readers can follow VERO news related to quarterly financial results, regulatory milestones, financing transactions and strategic portfolio moves. Recent press releases have covered second and third quarter financial results, including revenue by region and product category, gross profit trends, operating expenses and operating loss. Management commentary in these releases discusses the performance of energy-based device revenues, the impact of macroeconomic conditions on capital equipment sales, and the company’s efforts in cost containment and operational streamlining.
Venus Concept’s news also includes regulatory and product announcements, such as FDA 510(k) clearance for Venus NOVA, a multi-application platform for non-invasive body and skin treatments that integrates Adaptive EMS, proprietary (MP)² technology and Advanced VariPulse. In addition, the company reports on capital structure and financing events, including registered direct offerings of common stock, private placements of warrants, bridge loan drawdowns and debt-to-equity exchanges of subordinated convertible notes into Series Y Preferred Stock.
Another recurring theme in VERO news is the company’s strategic initiatives, notably the definitive agreement to sell its Venus Hair business, which includes NeoGraft and the ARTAS iX Robotic Hair Restoration system, to MHG Co. Ltd. Investors and observers can use this page to monitor how these developments evolve over time, from transaction announcements and court-related updates to subsequent financial disclosures.
Venus Concept (NASDAQ: VERO) reported Q2 2020 results with a 39% decline in revenue to $17.0 million, impacted by COVID-19. The company experienced a GAAP net loss of $13.2 million, significantly higher than the previous year's loss of $5.9 million. Operating loss rose to $9.2 million from $3.9 million in 2019. Cost savings from restructuring efforts reached $7.0 million, with a full-year target of $20.0 million. Notably, the company received FDA 510(k) clearance for the Venus Epileve device, enhancing its product offerings. Cash and equivalents stood at $14.0 million as of June 30, 2020.
Venus Concept (NASDAQ: VERO) reported preliminary revenue results for Q2 2020, with expected GAAP revenue between $16.4 million and $16.9 million, reflecting a 39% to 41% decline from $27.8 million in Q2 2019 due to COVID-19 impacts. CEO Domenic Serafino noted improvements as practices reopened, and highlighted strong growth from new product launches. The company projects $38 million in cost savings from ongoing restructuring initiatives, alongside a $31 million stock purchase agreement with Lincoln Park Capital to strengthen its financial position.
Venus Concept (NASDAQ: VERO) announced FDA 510(k) clearance for its Venus Viva MD, a non-invasive skin rejuvenation device. This new product enhances the company's offerings beyond the existing Venus Viva and Venus Versa. The Venus Viva MD features a new 80 pin tip design, increasing energy output for better treatment outcomes while maintaining safety. The device is aimed at dermatologists and plastic surgeons and is expected to drive long-term growth in the $3.4 billion global aesthetic market. A limited launch is anticipated by late Q3 2020.
Venus Concept (NASDAQ: VERO) announced its inclusion in the Russell 2000, Russell 3000, and Russell Microcap Indexes, effective after the US market close on June 26, 2020. This membership is significant as the Russell indexes are benchmarks for approximately $9 trillion in assets managed by investment professionals. CEO Domenic Serafino expressed optimism about the company's long-term prospects in the minimally invasive aesthetics and hair restoration market. The company's diverse product portfolio includes a range of aesthetic and hair restoration technologies, with operations in over 60 countries.
Venus Concept (NASDAQ: VERO) will release its second quarter fiscal 2020 financial results on August 13, 2020, after market close. A conference call is scheduled for 5:00 p.m. ET that day to discuss the results, with a Q&A session included. Participants can join by dialing 877-407-2991 (international: 201-389-0925) and using access code 13706095. The call will also be available via a live webcast on the company’s investor relations website, and a replay will be accessible for two weeks.
Venus Concept (VERO) has entered a common stock purchase agreement with Lincoln Park Capital for up to $31 million. An initial purchase of $1 million has been made. The company can sell shares over 24 months at prevailing market prices. This agreement aims to enhance Venus Concept's balance sheet, with expected cost savings of approximately $38 million in 2020 and 2021 from recent restructuring and merger synergies. Proceeds will support working capital and corporate purposes. The agreement includes no short selling from Lincoln Park and can be terminated by Venus Concept at any time.
Venus Concept (NASDAQ: VERO) announced FDA 510(k) clearance for its new hair removal device, Venus Epileve, designed for permanent hair reduction. This product expands the company's offerings in the U.S. aesthetics market, building upon its previously launched Venus Velocity. The Epileve features a versatile, portable design and is suitable for all skin types, including tanned skin. Its Internet of Things (IoT) integration aims to enhance treatment efficiency. The company anticipates the U.S. launch will bolster growth in the $1.4 billion global hair removal market.